Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
MDS clinical trials
Every US clinical trial registered for MDS — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
23 US clinical trials · 13 currently recruiting
The research picture
MDS has 23 registered US clinical trials, 13 of them open to new participants right now — about 57% of the total.
- 13
- recruiting participants now
- 57%
- of trials open to enrollment
- 1
- in Phase 3–4 (later-stage)
- 1
- top sponsor: Cyclacel Pharmaceuticals
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
A Long Term Follow-up Study of TScan TCR-T Products
TScan Therapeutics
NCT06976736
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
National Cancer Institute (NCI)
NCT01861106
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Stelexis BioSciences
NCT06533761
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
NCT05829226
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Marker Therapeutics
NCT06552416
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio
NCT06704152
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT05796570
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT04644016
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
University of Illinois at Chicago
NCT04187105
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Treebough Therapies
NCT07006025
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Abramson Cancer Center at Penn Medicine
NCT03680677
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT06326463
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Treadwell Therapeutics
NCT04730258
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta
NCT04623944
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
M.D. Anderson Cancer Center
NCT05285813
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
NCT05177211
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics
NCT03745716
Ascorbic Acid Levels in MDS, AML, and CMML Patients
Van Andel Research Institute
NCT03526666
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
Joanne Kurtzberg, MD
NCT00692926
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
Celyad Oncology
NCT03466320
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
NCT00185692
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals
NCT04017546
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the MDS Trial Landscape
ClinicalTrials.gov lists 23 US studies indexed under MDS, and 13 of those are currently open to recruitment — roughly 57% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for MDS shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 19 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for MDS is led by Cyclacel Pharmaceuticals with 1 indexed trial, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 23 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for MDS?
PlainTrial tracks 23 US clinical trials for MDS, of which 13 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for MDS?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.